History and Purpose
Our focus and resources are devoted to enhancing the established benchmark for organ transplant solutions: the UW solutions sold under the Belzer UW® trademark. Our initial research seeks to combine the cellular fuel ATP with our storage solution to greatly increase the longevity of preservation times, and the use of, donated organs. (See our Technical Discussion)
Bridge to Life is the exclusive licensee of the Belzer UW® trademark from the Wisconsin Alumni Research Foundation (WARF). A key assumption of the Bridge to Life business plan is to build and develop the expertise that exists at University of Wisconsin Madison (UW-Madison) as the pioneer in the organ transplant field.
Bridge to Life has licensed a unique fusogenic liposomal formulation of ATP (FL-ATP) to achieve the difficult goal of delivering bio-active ATP through the cell wall. This technology has additional potential medical applications including angioplasty, stent procedures, coronary artery bypass grafting, other post-heart attack therapies and tourniquet surgeries.